Rosiglitazone, a drug commonly used to treat diabetes, is associated with an increased risk of myocardial infarction, a study has shown.
The debate about the safety of the drug, manufactured by GlaxoSmithKline under the trade name Avandia, has been raging since the US Food and Drugs Administration issued a warning about the possible risk in February this year.
A previous study in the New England Journal of Medicine had warned of an increased risk of MI with rosiglitazone earlier this year.
The latest research pools data from four previous studies on rosiglitazone and found the drug increased the risk of MI by 42% and more than doubled the risk of heart failure. There was no increased risk of cardiovascular mortality.
But a spokesperson for GSK said: 'The JAMA article on rosiglitazone is yet another iteration of previously analysed data, and offers no new information on the safety of rosiglitazone.'
Journal of the American Medical Association (2007) 298:1189-1195